Log In
Print
BCIQ
Print
Print this Print this
 

HuMax-CD38, daratumumab

  Manage Alerts
Collapse Summary General Information
Company Genmab A/S
DescriptionHuman mAb against CD38
Molecular Target CD38
Mechanism of ActionAntibody
Latest Stage of DevelopmentPhase I/II
IndicationMultiple myeloma (MM)
Partner

Johnson & Johnson
 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today